The purpose of this study is to 1) evaluate the extent of absorption of a single dose of a pregabalin controlled release tablet following either a low, medium, or high-fat evening meal as compared to a single dose of the pregabalin immediate release capsule, 2) evaluate the safety and tolerability of a single dose of a pregabalin controlled release tablet following a low, medium, or high fat evening meal as compared to a single dose of the pregabalin immediate release capsule.
Evaluate the absorption, pharmacokinetics, safety/tolerability of a single dose of a pregabalin CR tablet under various conditions as compared to single dose of pregabalin IR capsule
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
28
A single oral dose of 330 mg controlled release tablet administered following a low-fat evening meal
A single oral dose of 330 mg controlled release tablet administered following a medium-fat evening meal
A single oral dose of 330 mg controlled release tablet administered following a high-fat evening meal
A single oral dose of 300 mg immediate release capsule administered following a medium-fat evening meal
Pfizer Investigational Site
Overland Park, Kansas, United States
Area under the curve from 0 to infinity (AUCinf) for assessment of equivalence between the controlled release treatments and the immediate release treatments
Time frame: 3 days
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Time frame: 3 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.